Janux Therapeutics logo

Janux Therapeutics

JANX | NASDAQ
Chart Builder DCF Calculator
$10.92
-$0.45 (-3.96%)
At close: Nov 16, 2026, 4:00 PM ET
$11.12
+$0.20 (+1.83%)
After-hours: Nov 16, 2026, 7:35 PM ET
-3.96%

Rating

Updated: Nov 16, 2026
38.7
-3.0 pts
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #565/1021 (Top 55%)

Key Statistics

Market Data

Market Cap $668.12M
1D Range
10.73 11.32
52W Range
10.73 34.74

Valuation (TTM)

PE -6.82
PB 0.73
EV/EBITDA 2.62

Valuation (NTM)

Forward PE N/A
Forward PEG 0.41
Price Target $30.50
Loading financial charts...

Profile

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technol...

Sector Healthcare
Industry Biotechnology
Employees 113
IPO Date Jun 11, 2021
Fiscal Year January - December

Latest News

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease

8 days ago · businesswire.com

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates

11 days ago · zacks.com

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

2 months ago · businesswire.com

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

3 months ago · zacks.com

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.34
Beat +28.19%
REV
$9.29M
Beat +15.69%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
13
Consensus
Buy
Price Target
$30.50
Upside
+179.30%
Buy (9)
Hold (3)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.